IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
SANGAMO THERAPEUTICS, INC.,[1]	Case No. 26-10989 (CTG)
Debtor.	**Obj. Deadline: November 12, 2026 at 4:00 p.m.**

SUMMARY OF SECOND MONTHLY APPLICATION OF DUNDON ADVISERS LLC, FINANCIAL ADVISOR TO THE OFFICIAL COMMITTEE OF EQUITY HOLDERS, FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD FROM SEPTEMBER 1, 2026 THROUGH SEPTEMBER 30, 2026

Name of Applicant	Dundon Advisers LLC
Authorized to provide professional services to:	Official Committee of Equity Holders of Sangamo Therapeutics, Inc.
Date of retention order:	September 17, 2026, effective as of August 5, 2026
Period for which compensation and reimbursement sought:	September 1, 2026 through September 30, 2026
Compensation sought as actual, reasonable, and necessary:	$277,699.60 (80% of $347,124.50)
Blended Hourly Rate:	$726.05
Expense reimbursement sought as actual, reasonable, and necessary:	$0.00
This is a(n):	_X_ monthly ___ interim ___ final

Previous Applications:

[1] The last four digits of the Debtor's federal tax identification number are 9556. The Debtor's principal office is located at 501 Canal Boulevard, Suite A100, Richmond, CA 94804.

2610989261022000000000003

Monthly Fee Application Filing Date & Docket No.	Period Covered	Total Fees Requested	Total Expenses Requested	CNO Filing Date & Docket No.	Amount of Fees Authorized to be Paid	Amount of Expenses Authorized to be Paid
09/29/2026 [D.I. 490]	August 5, 2026 – August 31, 2026	$328,154.50	$423.00	*Pending*	*Pending*	*Pending*

Note: The objection deadline for Dundon Adviser LLC's first monthly fee application has been extended to October 23, 2026 for the Office of the United States Trustee.

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
SANGAMO THERAPEUTICS, INC.,[1]	Case No. 26-10989 (CTG)
Debtor.	**Obj. Deadline: November 12, 2026 at 4:00 p.m.**

SECOND MONTHLY APPLICATION OF DUNDON ADVISERS LLC, FINANCIAL ADVISOR TO THE OFFICIAL COMMITTEE OF EQUITY HOLDERS, FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD FROM SEPTEMBER 1, 2026 THROUGH SEPTEMBER 30, 2026

Dundon Advisers LLC ("Dundon"), financial advisor to the Official Committee of Equity Holders (the "Equity Committee") of Sangamo Therapeutics, Inc., the above-captioned debtor (the "Debtor"), hereby submits its second monthly fee application (the "Application") pursuant to sections 330 and 331 of title 11 of the United States Code, 11 U.S.C. §§101 et seq, as amended (the "Bankruptcy Code") for allowance of compensation in the amount of $347,124.50 and reimbursement of expenses in the amount of $0.00 for the period from September 1, 2026 through September 30, 2026 (the "Compensation Period"), and in support thereof, Dundon respectfully represents as follows:

JURISDICTION AND VENUE

1. This Court has jurisdiction over this Application pursuant to 28 U.S.C. §1334. This is a core proceeding pursuant to 28 U.S.C. §157(b)(2)(A) and (B).

2. Venue of this proceeding and this Application is proper in this District pursuant to 28 U.S.C. §§1408 and 1409.

[1] The last four digits of the Debtor's federal tax identification number are 9556. The Debtor's principal office is located at 501 Canal Boulevard, Suite A100, Richmond, CA 94804.

3. The statutory predicate for the relief sought herein is sections 1103 and 331 of the Bankruptcy Code, Bankruptcy Rule 2016, and Local Rule 2016-1.

BACKGROUND

4. On June 23, 2026 (the "Petition Date"), the Debtor filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code (the "Chapter 11 Case").

5. The Debtor has continued in the possession of its property and has continued to operate and manage its business as Debtor in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. No trustee or examiner has been appointed in the Chapter 11 Case.

6. On July 20, 2026, the Debtor filed its *Motion of the Debtor for Entry of an Order Establishing Procedures for Interim Compensation and Reimbursement of Professionals* (the "Interim Compensation Motion") [Docket No. 145], and on July 30, 2026, the Court entered an order approving the Interim Compensation Motion (the "Interim Compensation Order") [Docket No. 205].

7. On August 5, 2026, the United States Trustee for the District of Delaware (the "United States Trustee") filed its *Notice of Appointment of Committee of Equity Holders* [Docket No. 256] of the five (5) member committee pursuant to section 1102(a)(1) of the Bankruptcy Code. Frank J. Foley subsequently withdrew from the Equity Committee.

8. On August 5, 2026, the Equity Committee selected Orrick, Herrington & Sutcliffe LLP as its lead counsel, Morris James LLP as its Delaware counsel, and Dundon as its financial advisor.

9. On August 31, 2026, the Equity Committee filed the *Application for Entry of an Order Authorizing the Retention and Employment of Dundon Advisers LLC as Financial Advisor*

to the Official Committee of Equity Holders Effective as of August 5, 2026 (the "Retention Application") [Docket No. 411].

10. On September 16, 2026, the United States Trustee filed its *Amended Notice of Appointment of Committee of Equity Holders* [Docket No. 457] of the five (5) member committee pursuant to section 1102(a)(1) of the Bankruptcy Code, reflecting the appointment of Kays Alali as a member of the Equity Committee.[2]

11. On September 17, 2026, the Court entered an order approving the Retention Application, effective as of August 5, 2026 [Docket No. 465].

12. A chart detailing the fees during the Compensation Period, by professional and by category, and a full and detailed statement describing the services rendered during the Compensation Period, by each professional at Dundon are both attached as **Exhibit A**.

13. The total sum due to Dundon for professional services rendered on behalf of the Equity Committee during the Compensation Period is $347,124.50. Dundon submits that the professional services rendered on behalf of the Equity Committee during this time were reasonable and necessary. The total time spent by Dundon for professional services rendered on behalf of the Equity Committee during the Compensation period is 478.10 hours.

14. Every effort has been made by Dundon to categorize daily time entries in accordance with the correct project category. However, in some instances, services overlap between project categories. Thus, some services may appear under more than one category, although in no instance is a specific time entry recorded more than once.

15. Although every effort has been made to include all fees and expenses incurred in

[2] The Equity Committee members are the following: (1) Kenneth Grossman; (2) Venkata Jalagam; (3) Kays Alali; (4) Adam Nagin; and (5) Charlestown Jupiter Fund, LLC.

the Compensation Period, some fees and expenses might not be included in this Application due to delays caused by accounting and processing during the Compensation Period. Dundon reserves the right to make further applications to the Court for allowance of such fees and expenses not included herein. Subsequent applications will be filed in accordance with the Bankruptcy Code, the Bankruptcy Rules, and the Interim Compensation Order.

16. Dundon incurred $0.00 in expenses during the Compensation Period.

CERTIFICATION OF COMPLIANCE AND WAIVER

17. The undersigned representative of Dundon certifies that he has reviewed the requirements of Local Rule 2016-1, and that the Application substantially complies with that Local Rule. To the extent that the Application does not comply in all respects with the requirements of Local Rule 2016-1, Dundon believes that such deviations are not material and respectfully requests that any such requirements be waived.

[*Remainder of Page Intentionally Left Blank*]

WHEREFORE, Dundon hereby requests pursuant to the procedures allowed in the Interim Compensation Order: (i) interim allowance of compensation for necessary and valuable professional services rendered to the Equity Committee in the amount of $347,124.50 and reimbursement of expenses in the amount of $0.00 for the period from September 1, 2026 through September 30, 2026; (ii) payment in the total amount of $277,699.60 (representing 80% of the total fees billed: ($347,124.50) and 100% of the expenses ($0.00) incurred during the Compensation Period); and (iii) such other relief as this Court deems just and proper.

Dated: October 22, 2026

DUNDON ADVISERS LLC

/s/ Joshua Nahas

Joshua Nahas
565 Fifth Avenue, 16th Floor
New York, NY 10017
Telephone: (212) 859-2000
E-mail: jn@dundon.com

Financial Advisor to the Official Committee of Equity Holders

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
SANGAMO THERAPEUTICS, INC.,[1]	Case No. 26-10989 (CTG)
Debtor.	**Obj. Deadline: November 12, 2026 at 4:00 p.m.**

NOTICE OF SECOND MONTHLY APPLICATION OF DUNDON ADVISERS LLC, FINANCIAL ADVISOR TO THE OFFICIAL COMMITTEE OF EQUITY HOLDERS, FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD FROM SEPTEMBER 1, 2026 THROUGH SEPTEMBER 30, 2026

PLEASE TAKE NOTICE that on October 22, 2026, Dundon Advisers LLC filed its second monthly application (the "Application") seeking compensation for services rendered and reimbursement of expenses incurred as financial advisor to the Official Committee of Equity Holders (the "Equity Committee") appointed in the above-referenced bankruptcy case for the period from September 1, 2026 through September 30, 2026 with the United States Bankruptcy Court for the District of Delaware (the "Court").

PLEASE TAKE FURTHER NOTICE that if you object to the relief sought by the Application, you are required to file a response to the Application, on or before **November 12, 2026 at 4:00 p.m. (ET)** with the Clerk of the United States Bankruptcy Court for the District of Delaware, 824 N. Market Street, 3rd Floor, Wilmington, Delaware 19801. At the same time, you must also serve a copy of the response upon undersigned counsel to the Equity Committee.

PLEASE TAKE FURTHER NOTICE THAT IF NO OBJECTIONS ARE FILED AND SERVED IN ACCORDANCE WITH THE ABOVE PROCEDURES, THEN 80% OF FEES AND 100% OF THE EXPENSES REQUESTED IN THE APPLICATION MAY BE PAID PURSUANT TO THE INTERIM COMPENSATION ORDER WITHOUT FURTHER HEARING OR ORDER OF THE COURT.

IF YOU FAIL TO RESPOND IN ACCORDANCE WITH THIS NOTICE, THE COURT MAY GRANT THE RELIEF DEMANDED BY THE APPLICATION WITHOUT FURTHER NOTICE OR HEARING.

[1] The last four digits of the Debtor's federal tax identification number are 9556. The Debtor's principal office is located at 501 Canal Boulevard, Suite A100, Richmond, CA 94804.

Dated: October 22, 2026

MORRIS JAMES LLP

/s/ Eric J. Monzo

Eric J. Monzo (DE Bar No. 5214)
Jason S. Levin (DE Bar No. 6434)
3205 Avenue North Blvd., Suite 100
Wilmington, DE 19803
Telephone: (302) 888-6800
Facsimile: (302) 571-1750
E-mail: emonzo@morrisjames.com
jlevin@morrisjames.com

-and-

ORRICK, HERRINGTON & SUTCLIFFE LLP
Nicholas Poli (admitted *pro hac vice*)
Mark Franke (admitted *pro hac vice*)
Michael Trentin (admitted *pro hac vice*)
Sean Hickey (admitted *pro hac vice*)
51 West 52nd Street
New York, NY 10019-6142
Telephone: (212) 506-5000
Facsimile: (212) 506-5151
E-mail: npoli@orrick.com
mfranke@orrick.com
mtrentin@orrick.com
shickey@orrick.com

Counsel to the Official Committee of Equity Holders

EXHIBIT A

Compensation By Project Category – Second Monthly Compensation Period

Project Category	Billable Time	Billable Amount
Business Analysis	331.90	$230,752.50
Committee Member/Professional Meetings & Communications	86.50	$73,153.00
Other Professionals' Retention and Fee Applications	38.50	$25,389.00
Plan and Disclosure Statement	8.90	$8,203.00
Case Administration	4.00	$3,484.00
Retention and Fee Applications	4.80	$3,370.00
Claims Analysis	2.10	$1,575.00
Investigations	0.90	$823.00
Sales Process	0.50	$375.00
Total	**478.10**	**$347,124.50**

Blended Hourly Rate: $726.05

Compensation By Professional – Second Monthly Compensation Period

Professional	Title	Hourly Rate	Billable Time	Billable Amount
Matthew Dundon	Principal	$1,220.00	0.30	$366.00
Joshua Nahas	Managing Director	$1,120.00	139.40	$156,128.00
Michael Whalen	Director	$865.00	5.10	$4,411.50
Christopher Podesfinski	Associate Director	$750.00	88.60	$66,450.00
Chris Kazantzis	Senior Associate	$550.00	138.40	$76,120.00
Rahul Mital	Senior Associate	$550.00	13.70	$7,535.00
Ty Chung	Associate	$390.00	32.30	$12,597.00
Brodie Galfus	Associate	$390.00	60.30	$23,517.00
Total			**478.10**	**$347,124.50**

Time Detail – Second Monthly Compensation Period

Professional	Entry Date	Client	Project Category	Description	Billable Time	Billable Amt
Brodie Galfus	09/02/2026	Sangamo Therapeutics	Business Analysis	Updated case studies for cash vehicles with substantial NOLs	2.80	$1,092.00
Brodie Galfus	09/02/2026	Sangamo Therapeutics	Business Analysis	Updated reorganization value presentation	1.10	$429.00
Brodie Galfus	09/02/2026	Sangamo Therapeutics	Business Analysis	Reviewed and finalized reorg value presentation	2.90	$1,131.00
Brodie Galfus	09/03/2026	Sangamo Therapeutics	Business Analysis	Turned comments for reorg value presentation	2.00	$780.00
Brodie Galfus	09/05/2026	Sangamo Therapeutics	Business Analysis	Completed final QA of reorganization value deck with CK	2.40	$936.00
Brodie Galfus	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attended meeting with committee regarding case updates	1.00	$390.00
Brodie Galfus	09/16/2026	Sangamo Therapeutics	Business Analysis	Researched and created excel for admin costs for post Reorg structure for a standalone plan with CK	1.70	$663.00
Brodie Galfus	09/17/2026	Sangamo Therapeutics	Business Analysis	Created standalone reorg cost structure presentation	1.60	$624.00
Brodie Galfus	09/17/2026	Sangamo Therapeutics	Business Analysis	Updated excel for admin costs for post Reorg structure for a standalone plan with CK	0.60	$234.00
Brodie Galfus	09/18/2026	Sangamo Therapeutics	Business Analysis	Updated budget analysis presentation	1.60	$624.00
Brodie Galfus	09/19/2026	Sangamo Therapeutics	Business Analysis	Refined forecasted plan costs with C. Kazantzis	1.80	$702.00
Brodie Galfus	09/19/2026	Sangamo Therapeutics	Business Analysis	Researching SPACs, De-SPACs, and alternative vehicles with C. Kazantzis	3.60	$1,404.00
Brodie Galfus	09/19/2026	Sangamo Therapeutics	Business Analysis	Created slides on plan considerations with C. Kazantzis	3.00	$1,170.00
Brodie Galfus	09/20/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Meeting with OEC to discuss updates and strategy	1.20	$468.00

Brodie Galfus	09/20/2026	Sangamo Therapeutics	Business Analysis	Modeled forecasted transaction and sources and uses with C. Kazantzis	3.90	$1,521.00
Brodie Galfus	09/20/2026	Sangamo Therapeutics	Business Analysis	Created excel exhibits on plan considerations with C. Kazantzis	2.50	$975.00
Brodie Galfus	09/20/2026	Sangamo Therapeutics	Business Analysis	Created slides on excel exhibits on plan considerations with C. Kazantzis	2.30	$897.00
Brodie Galfus	09/20/2026	Sangamo Therapeutics	Business Analysis	Updated presentation with comments from counsel	0.40	$156.00
Brodie Galfus	09/21/2026	Sangamo Therapeutics	Business Analysis	Refined plan considerations slides with C. Kazantzis	3.20	$1,248.00
Brodie Galfus	09/25/2026	Sangamo Therapeutics	Business Analysis	Revised excel exhibits for plan considerations deck to the OEC	2.30	$897.00
Brodie Galfus	09/25/2026	Sangamo Therapeutics	Business Analysis	Revised plan considerations deck to the OEC	2.60	$1,014.00
Brodie Galfus	09/27/2026	Sangamo Therapeutics	Business Analysis	Revised plan consideration deck with Orrick's comments	0.60	$234.00
Brodie Galfus	09/27/2026	Sangamo Therapeutics	Business Analysis	QA of key stakeholder presentation	0.60	$234.00
Brodie Galfus	09/27/2026	Sangamo Therapeutics	Business Analysis	QA of variance report presentation	0.40	$156.00
Brodie Galfus	09/28/2026	Sangamo Therapeutics	Business Analysis	Revised key stakeholder presentation with Orrick's comments	0.30	$117.00
Brodie Galfus	09/29/2026	Sangamo Therapeutics	Business Analysis	Revised reorganization model post FSI counter offer with C. Kazantzis	3.20	$1,248.00
Brodie Galfus	09/29/2026	Sangamo Therapeutics	Business Analysis	Revised plan consideration slides with C. Kazantzis	2.60	$1,014.00
Brodie Galfus	09/29/2026	Sangamo Therapeutics	Business Analysis	Met internally to discuss reorganized vehicle and leverage	0.80	$312.00
Brodie Galfus	09/29/2026	Sangamo Therapeutics	Business Analysis	Reviewed new FSI proposed plan	0.40	$156.00
Brodie Galfus	09/29/2026	Sangamo Therapeutics	Business Analysis	Reviewed reorganized vehicle acquisition ability model and slides with C. Kazantzis	1.80	$702.00

Brodie Galfus	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Meeting with the Equity Committee regarding case updates	1.80	$702.00
Brodie Galfus	09/30/2026	Sangamo Therapeutics	Business Analysis	Revised hypothetical acquisition in reorganized vehicle post OEC meeting	2.20	$858.00
Brodie Galfus	09/30/2026	Sangamo Therapeutics	Business Analysis	Updated plan consideration slides with new model	0.80	$312.00
Brodie Galfus	09/30/2026	Sangamo Therapeutics	Business Analysis	Internal team meeting reviewing revised deck plan consideration deck	0.30	$117.00
Totals For Brodie Galfus					**60.30**	**$23,517.00**
Chris Kazantzis	09/01/2026	Sangamo Therapeutics	Business Analysis	Reviewed DOMO as case study for cash vehicle with NOLs	1.80	$990.00
Chris Kazantzis	09/01/2026	Sangamo Therapeutics	Business Analysis	Reviewed P10 and Crossroads for vehicles with NOLs	4.20	$2,310.00
Chris Kazantzis	09/01/2026	Sangamo Therapeutics	Business Analysis	Reviewed Mr. Cooper and Covanta public filings as vehicles with NOLs	4.00	$2,200.00
Chris Kazantzis	09/01/2026	Sangamo Therapeutics	Business Analysis	Reviewed Kingsway Financial and IES public filings for information on vehicles with NOLs	3.50	$1,925.00
Chris Kazantzis	09/01/2026	Sangamo Therapeutics	Business Analysis	Call with J. Nahas discussing public vehicles with NOLs	0.20	$110.00
Chris Kazantzis	09/02/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with MERU to discuss post sale mechanics	1.00	$550.00
Chris Kazantzis	09/02/2026	Sangamo Therapeutics	Business Analysis	Reviewed alternative sponsor bid	2.20	$1,210.00
Chris Kazantzis	09/02/2026	Sangamo Therapeutics	Business Analysis	Created case study slides on vehicles with NOLs for reorganization value deck	5.60	$3,080.00
Chris Kazantzis	09/02/2026	Sangamo Therapeutics	Business Analysis	Drafted template slides of potential plan terms	2.40	$1,320.00
Chris Kazantzis	09/02/2026	Sangamo Therapeutics	Business Analysis	Analyzed WMIH trading premium to cash based on public filings	1.60	$880.00

Chris Kazantzis	09/02/2026	Sangamo Therapeutics	Business Analysis	Updated reorganized value analysis with trading premium and finalized draft of slides	2.30	$1,265.00
Chris Kazantzis	09/02/2026	Sangamo Therapeutics	Business Analysis	Worked with M. Whalen on plan terms	1.80	$990.00
Chris Kazantzis	09/03/2026	Sangamo Therapeutics	Business Analysis	Revised reorganization value deck based on feedback from J. Nahas	2.20	$1,210.00
Chris Kazantzis	09/03/2026	Sangamo Therapeutics	Business Analysis	Edited plan term outline per feedback from J. Nahas	1.60	$880.00
Chris Kazantzis	09/04/2026	Sangamo Therapeutics	Business Analysis	Revised reorganization value deck per feedback from Orrick	1.20	$660.00
Chris Kazantzis	09/05/2026	Sangamo Therapeutics	Business Analysis	Revised reorganization value slides per feedback from OEC	2.50	$1,375.00
Chris Kazantzis	09/05/2026	Sangamo Therapeutics	Business Analysis	Completed final QA of reorganization value deck with BG	2.40	$1,320.00
Chris Kazantzis	09/05/2026	Sangamo Therapeutics	Business Analysis	Call with J. Nahas discuss reorg value slides	0.10	$55.00
Chris Kazantzis	09/07/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Call with C. Podesfinski discussing retention comps	0.20	$110.00
Chris Kazantzis	09/07/2026	Sangamo Therapeutics	Business Analysis	Review historical retention comps analysis	0.70	$385.00
Chris Kazantzis	09/07/2026	Sangamo Therapeutics	Business Analysis	Call with J. Nahas discussing warrants	0.10	$55.00
Chris Kazantzis	09/08/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Researched banker retention applications with no funded debt	2.60	$1,430.00
Chris Kazantzis	09/08/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Calculated banker fees for comp set	2.80	$1,540.00
Chris Kazantzis	09/08/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Reviewed Raymond James retention app	0.80	$440.00
Chris Kazantzis	09/09/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Completed initial QA of retention comps analysis excel	1.30	$715.00
Chris Kazantzis	09/09/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Discussed RJ retention with Orrick	0.20	$110.00

Chris Kazantzis	09/09/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Reviewed retention comps with CP	0.30	$165.00
Chris Kazantzis	09/09/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Follow up call with Orrick discussing RJ retention	0.20	$110.00
Chris Kazantzis	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with the OEC to discuss case updates and plan strategy	1.00	$550.00
Chris Kazantzis	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with Debtors to discuss run rate spend	0.90	$495.00
Chris Kazantzis	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with Debtors to discuss reorg plan	0.70	$385.00
Chris Kazantzis	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with OEC to discuss case strategy and plans	1.70	$935.00
Chris Kazantzis	09/16/2026	Sangamo Therapeutics	Business Analysis	Forecasted costs for post reorg entity with BG	1.70	$935.00
Chris Kazantzis	09/17/2026	Sangamo Therapeutics	Business Analysis	Revised shellco costs with B. Galfus	0.60	$330.00
Chris Kazantzis	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Compile previous work to send to new OEC member	0.40	$220.00
Chris Kazantzis	09/18/2026	Sangamo Therapeutics	Business Analysis	Reviewed budget analysis deck	0.70	$385.00
Chris Kazantzis	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with J. Nahas discussing plan options and workstreams	0.10	$55.00
Chris Kazantzis	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with OEC to discuss case updates and strategy	1.40	$770.00
Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Business Analysis	Forecast plan alternatives and related costs	0.80	$440.00
Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member discussing analysis questions	0.70	$385.00

Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with J. Nahas discussing workstreams	0.10	$55.00
Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with J. Nahas discussing strategy and analysis	0.10	$55.00
Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with J. Nahas discussing costs forecast	0.20	$110.00
Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Business Analysis	Working session with B. Galfus refining plan costs forecast	1.80	$990.00
Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Business Analysis	Analyzed case studies on nol vehicles and PE stranded assets	2.10	$1,155.00
Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Business Analysis	Created slides on case studies of nol vehicles and PE stranded assets	1.50	$825.00
Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Business Analysis	Working session with B. Galfus researching spacs, despacs, and alternative vehicles	3.60	$1,980.00
Chris Kazantzis	09/19/2026	Sangamo Therapeutics	Business Analysis	Working session with B. Galfus creating slides on plan considerations	3.00	$1,650.00
Chris Kazantzis	09/20/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with OEC to discuss updates and strategy	1.20	$660.00
Chris Kazantzis	09/20/2026	Sangamo Therapeutics	Business Analysis	Working session with B. Galfus modeling forecasted transaction and sources and uses	3.90	$2,145.00
Chris Kazantzis	09/20/2026	Sangamo Therapeutics	Business Analysis	Working session with B. Galfus creating exhibits on plan considerations	2.50	$1,375.00
Chris Kazantzis	09/20/2026	Sangamo Therapeutics	Business Analysis	Working session with B. Galfus creating slides on exhibits for plan considerations	2.30	$1,265.00
Chris Kazantzis	09/21/2026	Sangamo Therapeutics	Business Analysis	Working session with B. Galfus refining plan considerations slides	3.20	$1,760.00
Chris Kazantzis	09/21/2026	Sangamo Therapeutics	Business Analysis	Finalized plan considerations draft deck	1.80	$990.00

Chris Kazantzis	09/22/2026	Sangamo Therapeutics	Retention and Fee Applications	Created exhibits for first monthly fee application and finalized draft	1.20	$660.00
Chris Kazantzis	09/22/2026	Sangamo Therapeutics	Business Analysis	Updated data room index	0.50	$275.00
Chris Kazantzis	09/22/2026	Sangamo Therapeutics	Retention and Fee Applications	Drafted first monthly fee application text	1.80	$990.00
Chris Kazantzis	09/23/2026	Sangamo Therapeutics	Business Analysis	Researched retained programs	2.90	$1,595.00
Chris Kazantzis	09/23/2026	Sangamo Therapeutics	Business Analysis	Created slides on retained programs	2.60	$1,430.00
Chris Kazantzis	09/24/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with OEC to discuss case updates and next steps	1.80	$990.00
Chris Kazantzis	09/25/2026	Sangamo Therapeutics	Business Analysis	Revised forecast of reorganized value	3.30	$1,815.00
Chris Kazantzis	09/25/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with JN discussing reorg value	0.50	$275.00
Chris Kazantzis	09/25/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with JN discussing reorg value slides	0.10	$55.00
Chris Kazantzis	09/25/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with JN discussing model inputs on potential reorg vehicle	0.20	$110.00
Chris Kazantzis	09/25/2026	Sangamo Therapeutics	Business Analysis	Updated forecast on future reorg vehicle	2.60	$1,430.00
Chris Kazantzis	09/25/2026	Sangamo Therapeutics	Business Analysis	Updated slides on plan considerations	2.30	$1,265.00
Chris Kazantzis	09/25/2026	Sangamo Therapeutics	Business Analysis	Reviewed reorg value slides with R. Mital	1.10	$605.00
Chris Kazantzis	09/26/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Internal call reviewing plan considerations slides	0.70	$385.00
Chris Kazantzis	09/26/2026	Sangamo Therapeutics	Business Analysis	Revised plan considerations slides with R. Mital post internal call	2.30	$1,265.00
Chris Kazantzis	09/26/2026	Sangamo Therapeutics	Business Analysis	Created excel exhibits for potential discussion with key stakeholder	1.80	$990.00
Chris Kazantzis	09/26/2026	Sangamo Therapeutics	Business Analysis	Created slides for discussion with key stakeholder	1.40	$770.00

Chris Kazantzis	09/26/2026	Sangamo Therapeutics	Business Analysis	Worked with R. Mital to update reorg forecast	1.70	$935.00
Chris Kazantzis	09/26/2026	Sangamo Therapeutics	Business Analysis	Worked with R. Mital to update reorg forecast slides	1.30	$715.00
Chris Kazantzis	09/27/2026	Sangamo Therapeutics	Business Analysis	Reviewed updates to plan considerations slides per feedback from Orrick	0.50	$275.00
Chris Kazantzis	09/27/2026	Sangamo Therapeutics	Business Analysis	Reviewed variance report week ending 9/18	0.40	$220.00
Chris Kazantzis	09/28/2026	Sangamo Therapeutics	Business Analysis	Revised slides for discussion with key stakeholder	0.30	$165.00
Chris Kazantzis	09/28/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Calls with JN discussing updates to slides for key stakeholder	0.20	$110.00
Chris Kazantzis	09/29/2026	Sangamo Therapeutics	Business Analysis	Worked with B. Galfus to revise reorganization model post FSI counter offer	3.20	$1,760.00
Chris Kazantzis	09/29/2026	Sangamo Therapeutics	Business Analysis	Updated plan considerations slides with B. Galfus	2.60	$1,430.00
Chris Kazantzis	09/29/2026	Sangamo Therapeutics	Business Analysis	Met internally to discuss reorganized vehicle and leverage	0.80	$440.00
Chris Kazantzis	09/29/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Reviewed new proposed plan	0.50	$275.00
Chris Kazantzis	09/29/2026	Sangamo Therapeutics	Business Analysis	Revised reorganized vehicle acquisition ability model and slides with B. Galfus	1.80	$990.00
Chris Kazantzis	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with OEC to discuss FSI bid and next steps	1.80	$990.00
Chris Kazantzis	09/30/2026	Sangamo Therapeutics	Business Analysis	Revised reorg value model and slides post feedback from OEC meeting	3.10	$1,705.00
Chris Kazantzis	09/30/2026	Sangamo Therapeutics	Business Analysis	Met internally to review revised plan considerations deck	0.30	$165.00
Chris Kazantzis	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with J. Nahas on reorg value slides	0.30	$165.00

Chris Kazantzis	09/30/2026	Sangamo Therapeutics	Business Analysis	Created plan consideration slides and exhibits for Debtor discussion materials	2.40	$1,320.00
Chris Kazantzis	09/30/2026	Sangamo Therapeutics	Business Analysis	Revised plan consideration slides and exhibits for Debtor discussion materials per feedback from J. Nahas and Orrick	2.30	$1,265.00
Totals For Chris Kazantzis					**138.40**	**$76,120.00**
Christopher Podesfinski	09/01/2026	Sangamo Therapeutics	Business Analysis	Discussion with J. Nahas regarding budget	0.40	$300.00
Christopher Podesfinski	09/01/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Review first monthly fee application of UCC counsel (D.I. 416)	0.40	$300.00
Christopher Podesfinski	09/01/2026	Sangamo Therapeutics	Business Analysis	Additional QA of warrant holder table based on missing warrants in v1 version (.9); email to Debtor FA regarding possible issue with exercise price of certain warrants.	1.00	$750.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with Debtor FA discussing warrants; term sheet	0.20	$150.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Business Analysis	Review original DIP budget and compare overlapping period in replacement DIP	1.50	$1,125.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with MERU discussing warrants, operations post sale, term sheets, etc.	1.00	$750.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Business Analysis	Review MERU's maximum exercisable warrant analysis	0.30	$225.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Business Analysis	Call with J. Nahas discussing professional fee schedule	0.10	$75.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Business Analysis	Call with T. Chung discussing professional fee analysis	0.10	$75.00

Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Business Analysis	Review/QA T. Chung analysis of professional fee schedule	0.30	$225.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Business Analysis	Call with T. Chung making incremental updates to blended budget/professional fee schedule analysis	0.10	$75.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review counsel's email regarding FSI	0.10	$75.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Business Analysis	Research on L5 election for NOLs	0.40	$300.00
Christopher Podesfinski	09/02/2026	Sangamo Therapeutics	Business Analysis	Review counsel's letter to potential plan sponsor	0.30	$225.00
Christopher Podesfinski	09/03/2026	Sangamo Therapeutics	Business Analysis	Review and comment on updated Committee deck discussing reorg value and case studies	2.10	$1,575.00
Christopher Podesfinski	09/03/2026	Sangamo Therapeutics	Business Analysis	Close out research into D&Os	1.40	$1,050.00
Christopher Podesfinski	09/04/2026	Sangamo Therapeutics	Business Analysis	Review counsel's comments on reorg deck	0.10	$75.00
Christopher Podesfinski	09/04/2026	Sangamo Therapeutics	Business Analysis	Review further revised Committee deck post counsel's updates	0.60	$450.00
Christopher Podesfinski	09/05/2026	Sangamo Therapeutics	Business Analysis	Review Committee member revisions to reorg. deck and final deck post updates	0.60	$450.00
Christopher Podesfinski	09/07/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Call with C. Kazantzis discussing banker retention comp workstreams	0.20	$150.00
Christopher Podesfinski	09/07/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Search previous engagements for comps for Raymond James retention	1.20	$900.00
Christopher Podesfinski	09/07/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Review/comment on "off the shelf" banker comps escalated by C. Kazantzis	1.00	$750.00
Christopher Podesfinski	09/08/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with Debtor FA discussing case strategy, workstreams, Dundon retention	0.30	$225.00

Christopher Podesfinski	09/08/2026	Sangamo Therapeutics	Retention and Fee Applications	Draft responses for Debtor's counsel regarding Dundon retention	0.30	$225.00
Christopher Podesfinski	09/09/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	2 calls with counsel discussing retention comps	0.20	$150.00
Christopher Podesfinski	09/09/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Call with C. Kazantzis discussing retention comps	0.30	$225.00
Christopher Podesfinski	09/09/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	QA of current banker comp set and research additional comps to include based on case facts	4.30	$3,225.00
Christopher Podesfinski	09/09/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with Debtor FA discussing RJ engagement letter and winddown budgets	0.30	$225.00
Christopher Podesfinski	09/09/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Follow up call with counsel discussing RJ engagement letter/possible fees payable	0.20	$150.00
Christopher Podesfinski	09/09/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Continued research in Octus regarding banker engagement letters regarding rx fees/offsets or credits against other fees/sourcing two DIPs	1.80	$1,350.00
Christopher Podesfinski	09/10/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Incremental updates to latest version of banker comps with two new examples	1.40	$1,050.00
Christopher Podesfinski	09/10/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Email to internal team regarding historical banker retention involving fee credits with examples	0.40	$300.00
Christopher Podesfinski	09/10/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Discussion with J. Nahas regarding interpretation of certain clauses in Raymond James engagement letter	0.60	$450.00
Christopher Podesfinski	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend Committee member meeting discussing case strategy, banker fees, etc.	1.00	$750.00

Christopher Podesfinski	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with MERU and Debtor mgmt. discussing program costs and current state of sale process	0.90	$675.00
Christopher Podesfinski	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with Raymond James and MERU discussing Dundon's reorg value materials	0.70	$525.00
Christopher Podesfinski	09/11/2026	Sangamo Therapeutics	Sales Process	Review alternative restructuring proposal sent by Committee member	0.30	$225.00
Christopher Podesfinski	09/11/2026	Sangamo Therapeutics	Retention and Fee Applications	Assist counsel with further redlines to Dundon's retention application	0.20	$150.00
Christopher Podesfinski	09/11/2026	Sangamo Therapeutics	Business Analysis	Research into company mentioned by Committee member possibly interested in alternative transaction	1.40	$1,050.00
Christopher Podesfinski	09/12/2026	Sangamo Therapeutics	Retention and Fee Applications	Response to counsel regarding update text for retention order for Dundon	0.10	$75.00
Christopher Podesfinski	09/13/2026	Sangamo Therapeutics	Case Administration	Review pending open items sent by counsel	0.10	$75.00
Christopher Podesfinski	09/13/2026	Sangamo Therapeutics	Business Analysis	Research on EDGAR reviewing statements of beneficial ownership (1.6); email to Debtor FA regarding "missing" shareholder (.1)	1.70	$1,275.00
Christopher Podesfinski	09/13/2026	Sangamo Therapeutics	Business Analysis	Re-review of D&O insurance policies	0.60	$450.00
Christopher Podesfinski	09/13/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Review first fee applications for Cooley, RLF and MERU (1.0) and create budget/actuals to date schedule (.7)	1.70	$1,275.00
Christopher Podesfinski	09/13/2026	Sangamo Therapeutics	Business Analysis	Begin review of updated/overlapping budget analysis deck	1.00	$750.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Business Analysis	Discussion with T. Chung reviewing and proposing updates to budget analysis deck	0.20	$150.00

Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review multiple emails from Committee members and counsel regarding letter to board and plan term sheet	0.30	$225.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Case Administration	Review further revised letter to board regarding mgmt. led plan	0.40	$300.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Business Analysis	Review revised Dundon materials on replacement budget analysis	0.90	$675.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Review OEC draft plan term sheet	0.80	$600.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Business Analysis	Research into AAV9 delivery methods, deaths, context to adverse events, etc.	4.20	$3,150.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Rereview of interim compensation order	0.20	$150.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with J. Nahas discussing budget and short term workstreams	0.40	$300.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Business Analysis	Rereview of DIP budget final order regarding variance testing, etc.	0.30	$225.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Internal email describing findings related to AAV9	0.40	$300.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Business Analysis	Review budget variance report as of 9/3	0.30	$225.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Review redlines to OEC plan term sheet (.2); email to counsel regarding NOL values (.2)	0.40	$300.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Business Analysis	Review updated budget forecast with bridge	1.20	$900.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Business Analysis	Call with J. Nahas discussing extended budget provided today	0.20	$150.00
Christopher Podesfinski	09/14/2026	Sangamo Therapeutics	Business Analysis	Call with MERU discussing extended budget assumptions	0.20	$150.00

Christopher Podesfinski	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review counsel's emails to Committee members discussing case updates	0.20	$150.00
Christopher Podesfinski	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review emails between counsel and Committee member regarding plan term sheet/case strategy	0.20	$150.00
Christopher Podesfinski	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Read letter from Committee member to professionals and other members regarding case strategy	0.20	$150.00
Christopher Podesfinski	09/15/2026	Sangamo Therapeutics	Business Analysis	Review KEIP/KERP materials put together by Debtor FA	1.30	$975.00
Christopher Podesfinski	09/15/2026	Sangamo Therapeutics	Business Analysis	Search Octus/dockets for KEIP/KERP comps used in Debtor materials	3.50	$2,625.00
Christopher Podesfinski	09/15/2026	Sangamo Therapeutics	Investigations	Review 2004 requests to Debtor	0.50	$375.00
Christopher Podesfinski	09/15/2026	Sangamo Therapeutics	Business Analysis	Review/formula check of new forecast (WE 9/11) in excel	0.50	$375.00
Christopher Podesfinski	09/15/2026	Sangamo Therapeutics	Business Analysis	Review and comment on latest forecast presentation + variance report (as of 9/4)	0.80	$600.00
Christopher Podesfinski	09/16/2026	Sangamo Therapeutics	Business Analysis	Review weekly actuals June through September 4.	1.00	$750.00
Christopher Podesfinski	09/16/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review Debtor's letter in response to OEC letter to board	0.20	$150.00
Christopher Podesfinski	09/16/2026	Sangamo Therapeutics	Business Analysis	Review Nav 1.7 projections and scenario analysis	0.80	$600.00
Christopher Podesfinski	09/16/2026	Sangamo Therapeutics	Business Analysis	Review and provide feedback on combined actuals + forecast analysis materials prepared by T. Chung	1.10	$825.00
Christopher Podesfinski	09/17/2026	Sangamo Therapeutics	Case Administration	Review emails from counsel and Committee members regarding governance	0.30	$225.00

Christopher Podesfinski	09/17/2026	Sangamo Therapeutics	Case Administration	Review updated 9/18 meeting agenda and updated by-laws	0.50	$375.00
Christopher Podesfinski	09/17/2026	Sangamo Therapeutics	Business Analysis	Review forecasted plan costs (Dundon adjustments to Debtor cost projections)	0.40	$300.00
Christopher Podesfinski	09/17/2026	Sangamo Therapeutics	Business Analysis	Review latest BDO 382 report	1.00	$750.00
Christopher Podesfinski	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review Committee member email on NOL valuation	0.30	$225.00
Christopher Podesfinski	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review Debtor's email regarding FSI counterproposal	0.10	$75.00
Christopher Podesfinski	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend Committee member meeting discussing governance and case strategy	1.40	$1,050.00
Christopher Podesfinski	09/18/2026	Sangamo Therapeutics	Business Analysis	Review and incremental updates to latest version of budget analysis deck with latest forecast/bridge/variance report, etc.	2.20	$1,650.00
Christopher Podesfinski	09/19/2026	Sangamo Therapeutics	Business Analysis	Review email from Committee member regarding Committee position (.5); research on recently priced Nav transactions/included citations (3.0)	3.50	$2,625.00
Christopher Podesfinski	09/19/2026	Sangamo Therapeutics	Case Administration	Review redlines to by-laws proposed by Committee member	0.30	$225.00
Christopher Podesfinski	09/19/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Review FSI response to Debtor/OEC plan proposals	0.30	$225.00
Christopher Podesfinski	09/19/2026	Sangamo Therapeutics	Sales Process	Review J. Nahas email about royalty value	0.20	$150.00
Christopher Podesfinski	09/19/2026	Sangamo Therapeutics	Business Analysis	Review Dundon deck on standalone reorg costs	0.80	$600.00
Christopher Podesfinski	09/19/2026	Sangamo Therapeutics	Business Analysis	Email to MERU regarding budget line item question and review response	0.10	$75.00

Christopher Podesfinski	09/19/2026	Sangamo Therapeutics	Business Analysis	Additional review of 9/14 budget forecast	0.40	$300.00
Christopher Podesfinski	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Email to Committee members and counsel regarding budget/budget analysis	0.30	$225.00
Christopher Podesfinski	09/20/2026	Sangamo Therapeutics	Claims Analysis	Review counsel's email to Cooley regarding counter to FSI	0.10	$75.00
Christopher Podesfinski	09/20/2026	Sangamo Therapeutics	Business Analysis	Review Bloomberg article regarding NOLs in a comparable case	0.20	$150.00
Christopher Podesfinski	09/20/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review draft counsel's letter to Cooley regarding tax issues/execution risk	0.30	$225.00
Christopher Podesfinski	09/20/2026	Sangamo Therapeutics	Business Analysis	Review Dundon deck on FSI plan considerations/alternatives/costs of plan versus trust	2.30	$1,725.00
Christopher Podesfinski	09/20/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review Committee member and question list	1.00	$750.00
Christopher Podesfinski	09/21/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Review revised proposal to FSI	0.20	$150.00
Christopher Podesfinski	09/21/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review email exchanges between OEC and Debtor counsel regarding FSI proposal	0.10	$75.00
Christopher Podesfinski	09/21/2026	Sangamo Therapeutics	Case Administration	Review further revised bylaws/redlines	0.10	$75.00
Christopher Podesfinski	09/22/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Review Debtor's redlines to OEC proposal to FSI	0.10	$75.00
Christopher Podesfinski	09/22/2026	Sangamo Therapeutics	Business Analysis	Review notice of previously omitted contracts (D.I. 469)	0.10	$75.00
Christopher Podesfinski	09/23/2026	Sangamo Therapeutics	Business Analysis	Research into Committee member question about Fabry future liabilities	2.20	$1,650.00
Christopher Podesfinski	09/23/2026	Sangamo Therapeutics	Case Administration	Review of IRL regarding board minutes based on counsel's request	0.20	$150.00
Christopher Podesfinski	09/24/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend Committee member regarding case strategy, governance, etc. (partial attendance)	1.60	$1,200.00

Christopher Podesfinski	09/24/2026	Sangamo Therapeutics	Business Analysis	Additional background research on Mink Therapeutics	1.40	$1,050.00
Christopher Podesfinski	09/25/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review OEC/Debtor emails regarding warrants /plan	0.20	$150.00
Christopher Podesfinski	09/25/2026	Sangamo Therapeutics	Business Analysis	Review Debtor's 4 week variance report + commentary	0.40	$300.00
Christopher Podesfinski	09/25/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review emails between Debtor counsel and OEC counsel regarding FSI proposals	0.20	$150.00
Christopher Podesfinski	09/25/2026	Sangamo Therapeutics	Claims Analysis	Review of claims register post bar date	2.00	$1,500.00
Christopher Podesfinski	09/26/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review Committee member communication regarding FSI proposal issues	0.10	$75.00
Christopher Podesfinski	09/26/2026	Sangamo Therapeutics	Business Analysis	Review pipeline development opportunities deck	1.20	$900.00
Christopher Podesfinski	09/27/2026	Sangamo Therapeutics	Business Analysis	Review counsel's redlines to Dundon's plan consideration deck	0.30	$225.00
Christopher Podesfinski	09/27/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Review of plan considerations deck (FSI versus standalone)	2.20	$1,650.00
Christopher Podesfinski	09/28/2026	Sangamo Therapeutics	Retention and Fee Applications	Compose message to Committee members regarding Dundon fee application comments/filing	0.20	$150.00
Christopher Podesfinski	09/28/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review email from counsel regarding forthcoming FSI counter proposal	0.10	$75.00
Christopher Podesfinski	09/28/2026	Sangamo Therapeutics	Business Analysis	Review draft presentation to key shareholder	1.00	$750.00
Christopher Podesfinski	09/28/2026	Sangamo Therapeutics	Business Analysis	Review Dundon created variance report presentation for the week ending 9/18	0.40	$300.00
Christopher Podesfinski	09/29/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review Committee member feedback on plan consideration presentation	0.20	$150.00

Christopher Podesfinski	09/29/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review J. Nahas responses to Committee member questions on plan consideration presentation	0.10	$75.00
Christopher Podesfinski	09/29/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with MERU discussing warrant value/treatment; FSI plan, budget	0.50	$375.00
Christopher Podesfinski	09/29/2026	Sangamo Therapeutics	Business Analysis	Review Debtor responses and files related to discovery requests	0.50	$375.00
Christopher Podesfinski	09/29/2026	Sangamo Therapeutics	Business Analysis	Review/comment on revised plan consideration deck	0.40	$300.00
Christopher Podesfinski	09/30/2026	Sangamo Therapeutics	Business Analysis	Cross reference list of assigned contracts with UCC members	0.30	$225.00
Christopher Podesfinski	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend Committee member meeting voting on path forward/reviewing Dundon created materials	1.80	$1,350.00
Christopher Podesfinski	09/30/2026	Sangamo Therapeutics	Business Analysis	Internal meeting reviewing updates to plan consideration deck for debtor/Committee members	0.30	$225.00
Christopher Podesfinski	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review email from counsel about possible non consensual path forward	0.10	$75.00
Christopher Podesfinski	09/30/2026	Sangamo Therapeutics	Case Administration	Calendar upcoming important dates and milestones for the internal team	0.20	$150.00
Totals For Christopher Podesfinski					**88.60**	**$66,450.00**
Joshua Nahas	09/01/2026	Sangamo Therapeutics	Business Analysis	Call with CK discussing public companies with NOLs	0.20	$224.00
Joshua Nahas	09/01/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on public companies with NOLs	0.60	$672.00
Joshua Nahas	09/01/2026	Sangamo Therapeutics	Business Analysis	Reviewed public filings on cash vehicles with NOLs	4.60	$5,152.00

Joshua Nahas	09/01/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on value strategy	0.60	$672.00
Joshua Nahas	09/01/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on budget	0.40	$448.00
Joshua Nahas	09/01/2026	Sangamo Therapeutics	Business Analysis	Call with C. Podesfinski regarding budget	0.40	$448.00
Joshua Nahas	09/01/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Review fee application/time detail of MWS (UCC counsel)	0.70	$784.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Business Analysis	Reviewed and updated net proceeds analysis	2.10	$2,352.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg value	0.40	$448.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Business Analysis	Reviewed first draft of reorg value slides	2.50	$2,800.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on NOLs	0.50	$560.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg value slides	0.40	$448.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Business Analysis	Review first draft of NOL vehicle case studies	3.40	$3,808.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Business Analysis	Analysis of combined original/replacement/updated replacement DIP budgets	1.40	$1,568.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Business Analysis	Check of MERU's warrants analysis; review the public filings for accuracy of inputs	0.80	$896.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Business Analysis	Call with C. Podesfinski discussing budget line items	0.10	$112.00
Joshua Nahas	09/02/2026	Sangamo Therapeutics	Business Analysis	Review and multiple rounds of comments on counsel's letter to potential plan sponsor	1.40	$1,568.00

Joshua Nahas	09/02/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with MERU discussing strategy, NOLs, warrants, term sheets.	1.00	$1,120.00
Joshua Nahas	09/03/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg value analysis	0.60	$672.00
Joshua Nahas	09/03/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on strategy	0.50	$560.00
Joshua Nahas	09/03/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on required plan terms and governance	0.50	$560.00
Joshua Nahas	09/03/2026	Sangamo Therapeutics	Business Analysis	Research additional NOL vehicles and PORs from similarly situated companies	2.60	$2,912.00
Joshua Nahas	09/03/2026	Sangamo Therapeutics	Business Analysis	Multiple rounds of review and feedback on Committee member materials discussing NOL case studies, reorg value, plan term sheets	4.30	$4,816.00
Joshua Nahas	09/03/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with M. Whalen on presentation updates	0.20	$224.00
Joshua Nahas	09/04/2026	Sangamo Therapeutics	Business Analysis	Reviewed revised reorganization value slides with updated proceeds analysis	3.60	$4,032.00
Joshua Nahas	09/04/2026	Sangamo Therapeutics	Business Analysis	Reviewed reorganization value slides post updates from Orrick	0.80	$896.00
Joshua Nahas	09/04/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg slides	0.40	$448.00
Joshua Nahas	09/04/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on liquidity forecast and assumptions	0.70	$784.00

Joshua Nahas	09/04/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on plan proposal	0.50	$560.00
Joshua Nahas	09/04/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on future funding obligations	0.50	$560.00
Joshua Nahas	09/05/2026	Sangamo Therapeutics	Business Analysis	Review "final" reorg value deck to Debtor counsel post Committee member changes	2.60	$2,912.00
Joshua Nahas	09/05/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg value slides	0.80	$896.00
Joshua Nahas	09/05/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on NOL vehicles	0.60	$672.00
Joshua Nahas	09/05/2026	Sangamo Therapeutics	Business Analysis	Call with CK on reorg slides	0.10	$112.00
Joshua Nahas	09/07/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on warrants and plan	0.70	$784.00
Joshua Nahas	09/07/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg value	0.60	$672.00
Joshua Nahas	09/07/2026	Sangamo Therapeutics	Business Analysis	Re-review warrants documents and Orrick analysis	1.30	$1,456.00
Joshua Nahas	09/07/2026	Sangamo Therapeutics	Business Analysis	Call with CK on warrants	0.10	$112.00
Joshua Nahas	09/08/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on plan alternatives	0.50	$560.00
Joshua Nahas	09/08/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on plan offers	0.40	$448.00
Joshua Nahas	09/09/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on strategy	0.60	$672.00

Joshua Nahas	09/09/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg value	0.40	$448.00
Joshua Nahas	09/09/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Review and provide comments on current comp set for banker (.9); search Octus for additional examples for team to research (1.5)	2.40	$2,688.00
Joshua Nahas	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on forecasted costs and strategy	0.70	$784.00
Joshua Nahas	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on plan value and negotiations	0.50	$560.00
Joshua Nahas	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with RJ and MERRU reviewing Dundon's materials on reorg value/benefits	0.70	$784.00
Joshua Nahas	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend and present at Committee call discussing case strategy and RJ fees	1.00	$1,120.00
Joshua Nahas	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with MERU and Debtor mgmt. discussing program costs and current FSI bid	0.90	$1,008.00
Joshua Nahas	09/10/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Review email from C. Podesfinski regarding examples of banker fee credits for multiple transactions for similarly situated cases	0.20	$224.00
Joshua Nahas	09/10/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Rereview of Raymond James engagement letter and related order	0.60	$672.00
Joshua Nahas	09/10/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Review latest version of i-banker comp set with additional comps	0.80	$896.00

Joshua Nahas	09/10/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Call with C. Podesfinski regarding interpretation of certain clauses in Raymond James EL including Debtor FA and OEC counsel interpretations	0.60	$672.00
Joshua Nahas	09/11/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on plan	0.50	$560.00
Joshua Nahas	09/11/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg	0.40	$448.00
Joshua Nahas	09/11/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on alternatives and tax implications	0.40	$448.00
Joshua Nahas	09/11/2026	Sangamo Therapeutics	Retention and Fee Applications	Provide additional comments on Dundon retention order	0.20	$224.00
Joshua Nahas	09/13/2026	Sangamo Therapeutics	Case Administration	Review counsel's open items list	0.10	$112.00
Joshua Nahas	09/13/2026	Sangamo Therapeutics	Business Analysis	Confirm C. Podesfinski findings on Edgar regarding disclosures of large shareholders	1.00	$1,120.00
Joshua Nahas	09/13/2026	Sangamo Therapeutics	Business Analysis	Check of D&O insurance and send to counsel	0.90	$1,008.00
Joshua Nahas	09/13/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Review budget to actuals schedule for June/July fee applications	0.50	$560.00
Joshua Nahas	09/13/2026	Sangamo Therapeutics	Retention and Fee Applications	Provide additional comments to counsel on proposed order to Dundon retention application	0.30	$336.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on postpetition expenses and plan	0.40	$448.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on board letter	0.40	$448.00

Joshua Nahas	09/14/2026	Sangamo Therapeutics	Business Analysis	Provide comments on updated budget/bridge analysis materials created by T. Chung/C. Podesfinski	0.80	$896.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review emails from OEC members and counsel regarding board letter/plan term sheet	0.40	$448.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Case Administration	Review further revised letter to board regarding mgmt. reorg.	0.30	$336.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Review OEC draft plan term sheet	0.60	$672.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with C. Podesfinski discussing budget and necessary workstreams	0.40	$448.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review C. Podesfinski email regarding finding of other AAVP clinical trials	0.10	$112.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Business Analysis	Review latest budget variance report	0.40	$448.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Email to counsel regarding including NOL values in draft plan term sheet (.1) post reviewing latest redlines (.3)	0.40	$448.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Business Analysis	Review 9/14 budget reforecast with bridge	0.90	$1,008.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Business Analysis	Call with C. Podesfinski discussing extended budget assumptions	0.20	$224.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Investigations	Review 2004 requests counsel sent to Debtor	0.40	$448.00
Joshua Nahas	09/14/2026	Sangamo Therapeutics	Business Analysis	Read Debtor's KEIP/KERP analysis (.7); review historical Dundon created KEIP/KERP comps (2)	2.70	$3,024.00
Joshua Nahas	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on plan terms	0.70	$784.00
Joshua Nahas	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on remaining assets	0.40	$448.00

Joshua Nahas	09/15/2026	Sangamo Therapeutics	Business Analysis	Read through AAV9 related clinical trials and additional internet research attempting to find additional trials	3.20	$3,584.00
Joshua Nahas	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Read letter from Committee member to professionals/members	0.20	$224.00
Joshua Nahas	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review emails between counsel and Committee member regarding plan term sheet/case strategy	0.20	$224.00
Joshua Nahas	09/15/2026	Sangamo Therapeutics	Business Analysis	Continued research (internet/data room) into SGMO developmental drugs	3.40	$3,808.00
Joshua Nahas	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Participated in call with OEC discussing case updates and strategy	1.70	$1,904.00
Joshua Nahas	09/16/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on budget	0.50	$560.00
Joshua Nahas	09/16/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on path forward	0.40	$448.00
Joshua Nahas	09/16/2026	Sangamo Therapeutics	Business Analysis	Review actuals June through September 4.	1.10	$1,232.00
Joshua Nahas	09/16/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review Debtor's letter in response to OEC letter to board	0.20	$224.00
Joshua Nahas	09/16/2026	Sangamo Therapeutics	Business Analysis	Review Nav 1.7 projections and scenario analysis	0.70	$784.00
Joshua Nahas	09/16/2026	Sangamo Therapeutics	Business Analysis	Provide comments on further revised Dundon budget analysis deck	0.60	$672.00
Joshua Nahas	09/17/2026	Sangamo Therapeutics	Case Administration	Email to/from myself, counsel, Committee members regarding governance	0.40	$448.00

Joshua Nahas	09/17/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on plan options	0.70	$784.00
Joshua Nahas	09/17/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on shift	0.60	$672.00
Joshua Nahas	09/17/2026	Sangamo Therapeutics	Case Administration	Meeting with M. Dundon discussing case status	0.30	$336.00
Joshua Nahas	09/17/2026	Sangamo Therapeutics	Case Administration	Review updated bylaws	0.30	$336.00
Joshua Nahas	09/17/2026	Sangamo Therapeutics	Business Analysis	Review and comment on adjustments to forecasted plan costs	0.50	$560.00
Joshua Nahas	09/17/2026	Sangamo Therapeutics	Business Analysis	Review updated 382 report produced by BDO	0.80	$896.00
Joshua Nahas	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on FSI proposal	0.70	$784.00
Joshua Nahas	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on plan analysis	0.40	$448.00
Joshua Nahas	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on NOLs	0.40	$448.00
Joshua Nahas	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review Committee member email on NOL value	0.30	$336.00
Joshua Nahas	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Review Debtor's email regarding FSI counterproposal (.1); follow-up emails to Committee members/counsel (.2)	0.30	$336.00
Joshua Nahas	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend Committee member hearing discussing governance and case strategy	1.40	$1,568.00
Joshua Nahas	09/18/2026	Sangamo Therapeutics	Business Analysis	Review and approve for distribution final version of budget analysis materials	1.30	$1,456.00

Joshua Nahas	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with CK on plan considerations analysis	0.10	$112.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on NOLs	0.50	$560.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on path options	0.60	$672.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Email to MERU regarding cost estimates for remnant programs (.1); review response from MERU (.2)	0.30	$336.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Case Administration	Review Committee member redlines to bylaws	0.20	$224.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Review FSI response to separate Debtor/OEC plan proposals	0.30	$336.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Write email regarding value of royalty	0.30	$336.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Business Analysis	Review and provide comments on updated Dundon presentation on standalone reorg costs	0.60	$672.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Business Analysis	Review/analysis of NAV related precedent transactions	3.60	$4,032.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with CK discussing future work product	0.10	$112.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with CK discussing plan analysis	0.10	$112.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with CK refining costs forecast	0.10	$112.00
Joshua Nahas	09/19/2026	Sangamo Therapeutics	Business Analysis	Forecasted liquidating trust costs	1.40	$1,568.00

Joshua Nahas	09/20/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on plan analysis	0.50	$560.00
Joshua Nahas	09/20/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on strategy	0.40	$448.00
Joshua Nahas	09/20/2026	Sangamo Therapeutics	Business Analysis	Reviewed plan considerations slides	3.30	$3,696.00
Joshua Nahas	09/20/2026	Sangamo Therapeutics	Business Analysis	Reviewed reorganized value analysis (1.3) in relation to budget forecast (0.6)	1.90	$2,128.00
Joshua Nahas	09/20/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with OEC to discuss ongoing case developments	1.20	$1,344.00
Joshua Nahas	09/21/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on path forward	0.60	$672.00
Joshua Nahas	09/21/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on strategy and alternatives	0.70	$784.00
Joshua Nahas	09/21/2026	Sangamo Therapeutics	Business Analysis	Reviewed draft of plan considerations deck	3.50	$3,920.00
Joshua Nahas	09/23/2026	Sangamo Therapeutics	Retention and Fee Applications	Reviewed first monthly fee app	0.50	$560.00
Joshua Nahas	09/24/2026	Sangamo Therapeutics	Business Analysis	Reviewed slides on remaining programs	2.90	$3,248.00
Joshua Nahas	09/24/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Met with OEC discussing strategy	1.80	$2,016.00
Joshua Nahas	09/25/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with C. Kazantzis on reorg value excel	0.50	$560.00
Joshua Nahas	09/25/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with C. Kazantzis on reorg value slides	0.10	$112.00
Joshua Nahas	09/25/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with C. Kazantzis on reorg vehicle model	0.20	$224.00

Joshua Nahas	09/25/2026	Sangamo Therapeutics	Business Analysis	Reviewed reorg value model	2.30	$2,576.00
Joshua Nahas	09/25/2026	Sangamo Therapeutics	Business Analysis	Reviewed slides on reorg value	2.00	$2,240.00
Joshua Nahas	09/26/2026	Sangamo Therapeutics	Business Analysis	Continued review of reorg value and forecast	2.70	$3,024.00
Joshua Nahas	09/26/2026	Sangamo Therapeutics	Business Analysis	Reviewed next turn of plan considerations slides	2.40	$2,688.00
Joshua Nahas	09/26/2026	Sangamo Therapeutics	Business Analysis	Reviewed slides for discussion with large equity holder	1.50	$1,680.00
Joshua Nahas	09/27/2026	Sangamo Therapeutics	Business Analysis	Reviewed feedback from counsel on plan considerations slides	0.30	$336.00
Joshua Nahas	09/28/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with C. Kazantzis on slides for large equity holder	0.20	$224.00
Joshua Nahas	09/28/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg value and next steps	0.50	$560.00
Joshua Nahas	09/29/2026	Sangamo Therapeutics	Plan and Disclosure Statement	Reviewed FSI offer	3.50	$3,920.00
Joshua Nahas	09/29/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg value	0.50	$560.00
Joshua Nahas	09/29/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on FSI and strategy	0.80	$896.00
Joshua Nahas	09/29/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attended call with MERU regarding FSI plan, budget, and warrants	0.50	$560.00
Joshua Nahas	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attended meeting with OEC regarding FSI proposal and other case updates	1.80	$2,016.00
Joshua Nahas	09/30/2026	Sangamo Therapeutics	Business Analysis	Reviewed next turn of plan considerations deck	2.80	$3,136.00
Joshua Nahas	09/30/2026	Sangamo Therapeutics	Business Analysis	Drafted comments and feedback for team to incorporate in plan considerations slides	1.60	$1,792.00

Joshua Nahas	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with C. Kazantzis on reorg value slides	0.30	$336.00
Joshua Nahas	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on reorg value	0.50	$560.00
Joshua Nahas	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Call with OEC member on FSI proposal	0.70	$784.00
Totals For Joshua Nahas					**139.40**	**$156,128.00**
Matthew Dundon	09/17/2026	Sangamo Therapeutics	Business Analysis	Case status update with J. Nahas	0.30	$366.00
Totals For Matthew Dundon					**0.30**	**$366.00**
Michael Whalen	09/02/2026	Sangamo Therapeutics	Business Analysis	Work with Chris K. (partial) on making presentation for requested sponsor terms of Committee	1.80	$1,557.00
Michael Whalen	09/03/2026	Sangamo Therapeutics	Business Analysis	Work with team on pulling and calculating price/NAV and current yield for CEFs and BDCs	3.10	$2,681.50
Michael Whalen	09/03/2026	Sangamo Therapeutics	Business Analysis	Call with J. Nahas on terms presentation	0.20	$173.00
Totals For Michael Whalen					**5.10**	**$4,411.50**
Rahul Mital	09/25/2026	Sangamo Therapeutics	Business Analysis	Reviewed and analyzed FSI comparison deck	1.20	$660.00
Rahul Mital	09/25/2026	Sangamo Therapeutics	Business Analysis	Summarized rights offering and updated slides with Chris K.	1.10	$605.00
Rahul Mital	09/25/2026	Sangamo Therapeutics	Business Analysis	Advise on updated language for update acquisition ability	1.00	$550.00
Rahul Mital	09/26/2026	Sangamo Therapeutics	Business Analysis	Internal call reviewing plan considerations slides	0.70	$385.00
Rahul Mital	09/26/2026	Sangamo Therapeutics	Business Analysis	Revised plan considerations slides with C. Kazantzis	2.30	$1,265.00
Rahul Mital	09/26/2026	Sangamo Therapeutics	Business Analysis	Worked with C. Kazantzis to update reorg forecast	1.70	$935.00

Rahul Mital	09/26/2026	Sangamo Therapeutics	Business Analysis	Worked with C. Kazantzis to update reorg forecast slides	1.30	$715.00
Rahul Mital	09/26/2026	Sangamo Therapeutics	Business Analysis	Developed chart as per committee member for committee discussion on NOL usage	1.80	$990.00
Rahul Mital	09/29/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Meet with MERU on warrants	0.50	$275.00
Rahul Mital	09/30/2026	Sangamo Therapeutics	Business Analysis	Review revised deck on plan considerations	0.30	$165.00
Rahul Mital	09/30/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Meet with committee on FSI bid	1.80	$990.00
Totals For Rahul Mital					**13.70**	**$7,535.00**
Ty Chung	09/02/2026	Sangamo Therapeutics	Business Analysis	Meeting with CP on task (.1) + Create summary budget of professional fees through superseded budgets delivered (.7).	0.80	$312.00
Ty Chung	09/04/2026	Sangamo Therapeutics	Business Analysis	Presentation on replacement DIP cash flow forecast against previous	2.00	$780.00
Ty Chung	09/08/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Analysis on comparable banker fee structures	2.50	$975.00
Ty Chung	09/08/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Continue analysis on comparable banker fee structures	3.90	$1,521.00
Ty Chung	09/09/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Finalizing draft analysis on comparable banker fee structures	0.80	$312.00
Ty Chung	09/09/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Further continued analysis on comparable banker fee structures per feedback	0.90	$351.00
Ty Chung	09/09/2026	Sangamo Therapeutics	Case Administration	Distributing public filings to counsel	0.30	$117.00
Ty Chung	09/09/2026	Sangamo Therapeutics	Other Professionals' Retention and Fee Applications	Making updates to Raymond James banker fee structure comparison analysis	3.10	$1,209.00

Ty Chung	09/10/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend equity committee update call	1.00	$390.00
Ty Chung	09/14/2026	Sangamo Therapeutics	Business Analysis	Meeting with CP regarding presentation on replacement DIP budget forecast	0.20	$78.00
Ty Chung	09/14/2026	Sangamo Therapeutics	Business Analysis	Making updates to replacement DIP forecast presentation	1.40	$546.00
Ty Chung	09/14/2026	Sangamo Therapeutics	Business Analysis	Updating replacement DIP budget presentation and adding in variance reporting	2.10	$819.00
Ty Chung	09/14/2026	Sangamo Therapeutics	Business Analysis	Continue updating replacement DIP budget presentation with variance reporting received	0.40	$156.00
Ty Chung	09/15/2026	Sangamo Therapeutics	Business Analysis	Creating updated replacement DIP budget presentation for forecast received 9/14	0.70	$273.00
Ty Chung	09/15/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend equity committee meeting on proposed term sheet (left early)	1.50	$585.00
Ty Chung	09/15/2026	Sangamo Therapeutics	Business Analysis	Continue preparing & distribution of presentation on updated DIP forecast received 9/14 and variance reports	2.80	$1,092.00
Ty Chung	09/16/2026	Sangamo Therapeutics	Business Analysis	Updating replacement DIP budget presentation with newly received actuals figures.	1.20	$468.00
Ty Chung	09/18/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend committee meeting RE bylaws and Reorg proposals	1.40	$546.00
Ty Chung	09/18/2026	Sangamo Therapeutics	Business Analysis	Updating FSI replacement DIP presentation from internal comments	0.60	$234.00
Ty Chung	09/20/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend equity committee meeting	1.20	$468.00

Ty Chung	09/24/2026	Sangamo Therapeutics	Committee Member/Professional Meetings & Communications	Attend committee meeting discussing FSI, standalone reorg, plan sponsor, and professional engagements	1.80	$702.00
Ty Chung	09/27/2026	Sangamo Therapeutics	Business Analysis	Creating variance reporting presentation for the four weeks ended Sept. 18	1.40	$546.00
Ty Chung	09/30/2026	Sangamo Therapeutics	Business Analysis	Team meeting reviewing revised deck plan consideration deck	0.30	$117.00
Totals For Ty Chung					**32.30**	**$12,597.00**
			Total		**478.10**	**$347,124.50**

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
SANGAMO THERAPEUTICS, INC.,[1]	Case No. 26-10989 (CTG)
Debtor.	

DECLARATION OF JOSHUA NAHAS IN SUPPORT OF SECOND MONTHLY APPLICATION OF DUNDON ADVISERS LLC, FINANCIAL ADVISOR TO THE OFFICIAL COMMITTEE OF EQUITY HOLDERS, FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD FROM AUGUST 5, 2026 THROUGH AUGUST 31, 2026

I, Joshua Nahas, after being sworn according to law, depose and say:

1. I am a managing director at the firm of Dundon Advisers LLC ("Dundon"), financial advisor to the Official Committee of Equity Holders (the "Equity Committee").

2. I have read the foregoing *Second Monthly Application of Dundon Advisers LLC, Financial Advisor to the Official Committee of Equity Holders, for Allowance of Compensation and Reimbursement of Expenses for the Period from September 1, 2026 through September 30, 2026* and know the contents thereof. The same contents are true to the best of my knowledge, except as to matters therein alleged to be upon information and belief, and as to those matters, I believe them to be true. I have personally performed many of the services rendered by Dundon and am thoroughly familiar with all other work performed on behalf of the Equity Committee by the professionals at Dundon.

3. In accordance with Rule 2016(a) of the Federal Rules of Bankruptcy Procedure and Section 504 of the Title 11, United States Code, no agreement or understanding exists between

[1] The last four digits of the Debtor's federal tax identification number are 9556. The Debtor's principal office is located at 501 Canal Boulevard, Suite A100, Richmond, CA 94804.

Dundon and any other person for the sharing of compensation to be received in connection with the above-captioned case.

4. I have reviewed the requirements of Local Rule 2016-1 of the United States Bankruptcy Court for the District of Delaware, and to the best of my knowledge, information and belief, this Application complies with Local Rule 2016-1.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge and belief.

Dated: October 22, 2026

/s/ Joshua Nahas
Joshua Nahas

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
SANGAMO THERAPEUTICS, INC.,[1]	Case No. 26-10989 (CTG)
Debtor.	

CERTIFICATE OF SERVICE

I hereby certify that on this 22nd day of October, 2026, I caused to be filed with the Court electronically, and I caused to be served a true and correct copy of the *Second Monthly Application of Dundon Advisers LLC, Financial Advisor to the Official Committee of Equity Holders, for Allowance of Compensation and Reimbursement of Expenses for the Period from September1, 2026 through September 30, 2026* upon the parties that are registered to receive notice via the Court's CM/ECF notification system, and an additional service was completed via electronic mail or first-class mail on the parties listed on the attached service list.

/s/ Eric J. Monzo
Eric J. Monzo (DE Bar No. 5214)

[1] The last four digits of the Debtor's federal tax identification number are 9556. The Debtor's principal office is located at 501 Canal Boulevard, Suite A100, Richmond, CA 94804.

Service List

Cullen D. Speckhart, Esq.
Lauren A. Reichardt, Esq.
Miriam Peguero Medrano, Esq.
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2157
cspeckhart@cooley.com
lreichardt@cooley.com
mpegueromedrano@cooley.com

-and-

Robert L. Eisenbach III, Esq.
COOLEY LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111-4004
reisenbach@cooley.com

-and-

Daniel J. DeFranceschi, Esq.
Amanda R. Steele, Esq.
Brendan J. Schlauch, Esq.
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 N. King Street
Wilmington, Delaware 19801
defranceschi@rlf.com
steele@rlf.com
schlauch@rlf.com

Counsel to the Debtor

Linda J. Casey, Esq.
The Office of the United States Trustee
for the District of Delaware
J. Caleb Boggs Federal Building
844 North King Street, Suite 2207
Wilmington, DE 19801
linda.casey@usdoj.gov

United States Trustee

David R. Hurst, Esq.
Andrew A. Mark, Esq.
MCDERMOTT WILL & SCHULTE LLP
The Brandywine Building
1000 N. West Street, Suite 1400
Wilmington, Delaware 19801
dhurst@mcdermottlaw.com
amark@mcdermottlaw.com

-and-

Darren Azman, Esq.
Kristin K. Going, Esq.
Lindsay Barca, Esq.
MCDERMOTT WILL & SCHULTE LLP
One Vanderbilt Avenue
New York, New York 10017-3852
dazman@mcdermottlaw.com
kgoing@mcdermottlaw.com
lbarca@mcdermottlaw.com

Counsel to the Official Committee of Unsecured Creditors

Nir Maoz, Esq.
N. Tanner Frei, Esq.
KTBS Law LLP
1801 Century Park East, 26th Floor
Los Angeles, CA 90067
nmaoz@ktbslaw.com
tfrei@ktbslaw.com

-and-

Robert F. Poppiti, Jr., Esq.
Young Conaway Stargatt & Taylor, LLP
1000 North King Street
Wilmington, DE 19801
rpoppiti@ycst.com

Counsel to the Replacement DIP Lender